2023
Iron promotes glycolysis to drive colon tumorigenesis
Liu Z, Villareal L, Goodla L, Kim H, Falcon D, Haneef M, Martin D, Zhang L, Lee H, Kremer D, Lyssiotis C, Shah Y, Lin H, Lin H, Xue X. Iron promotes glycolysis to drive colon tumorigenesis. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2023, 1869: 166846. PMID: 37579983, PMCID: PMC10530594, DOI: 10.1016/j.bbadis.2023.166846.Peer-Reviewed Original ResearchConceptsGlucose transporter 1Colorectal cancerColon tumorigenesisIron treatmentProgression of CRCCancer-related deathColon tumor growthCommon cancerGlucose levelsColon carcinogenesisGlucose metabolismTumor growthPharmacological inhibitionIntracellular glucose levelsTumor cellsTransporter 1Iron levelsTumor formationAerobic glycolysisPyruvate dehydrogenase kinase 3Excess ironCancerTreatmentGlycolytic productsTricarboxylic acid cycle intermediatesUrinary Biomarkers of Kidney Tubule Health and Mortality in Persons with CKD and Diabetes Mellitus
Vasquez-Rios G, Katz R, Levitan E, Cushman M, Parikh C, Kimmel P, Bonventre J, Waikar S, Schrauben S, Greenberg J, Sarnak M, Ix J, Shlipak M, Gutierrez O. Urinary Biomarkers of Kidney Tubule Health and Mortality in Persons with CKD and Diabetes Mellitus. Kidney360 2023, 4: e1257-e1264. PMID: 37533144, PMCID: PMC10547219, DOI: 10.34067/kid.0000000000000226.Peer-Reviewed Original ResearchConceptsKidney injury molecule-1Monocyte chemoattractant protein-1Kidney tubule healthCause-specific mortalityUrine biomarkersYKL-40Risk factorsCardiovascular deathCause mortalityHigh riskChitinase-3-like protein 1Greater riskHigher MCP-1Higher urine levelsUrine KIM-1Injury molecule-1Cause-specific deathMortality risk factorsProportional hazards regressionRisk of deathAdditional risk factorsProtein 1Cancer-related deathChemoattractant protein-1Alpha-1-microglobulinA novel defined pyroptosis-related gene signature predicts prognosis and correlates with the tumour immune microenvironment in lung adenocarcinoma
Chen Z, Ge L, Xu S, Li Q, Zhou L. A novel defined pyroptosis-related gene signature predicts prognosis and correlates with the tumour immune microenvironment in lung adenocarcinoma. Scientific Reports 2023, 13: 9921. PMID: 37337018, PMCID: PMC10279685, DOI: 10.1038/s41598-023-36720-1.Peer-Reviewed Original ResearchConceptsPyroptosis-related genesTumor-infiltrating immune cellsTumor mutational burdenLung adenocarcinomaImmune cellsMutational burdenPrognostic signaturePyroptosis-related gene signatureTumor microenvironmentGene Expression Omnibus (GEO) cohortSelection operator CoxImmune cell infiltrationRole of pyroptosisIndependent prognostic biomarkerTumor immune microenvironmentCox regression modelImmune checkpoint regulatorsCancer-related deathCancer Genome Atlas (TCGA) databaseSpearman correlation analysisFuture studiesImmune microenvironmentCell infiltrationLUAD patientsCommon causeHBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol
Cheng Z, Li L, Zhang Y, Ren Y, Gu J, Wang X, Zhao H, Lu H. HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol. Briefings In Bioinformatics 2023, 24: bbac601. PMID: 36736372, DOI: 10.1093/bib/bbac601.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaClinical stageImmune microenvironmentTumor sizeHepatitis B virus infectionLow alpha-fetoprotein levelsMetabolism-related proteinsRelevant subgroupsB virus infectionSevere liver dysfunctionGood liver functionHigh AFP levelsAlpha-fetoprotein levelsPrimary liver malignancySmaller tumor sizeLarger tumor sizeLower clinical stageHigher clinical stageCancer-related deathProliferation activityPrevention of HBVNear-normal levelsLow proliferation activityLiver dysfunctionHigh proliferation activityManagement of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
Merkin R, Chiang V, Goldberg S. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances In Medical Oncology 2023, 15: 17588359231175438. PMID: 37275964, PMCID: PMC10233588, DOI: 10.1177/17588359231175438.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsBrain metastasesTargetable genetic alterationsLocal therapyLung cancerStereotactic radiosurgeryDeath 1 ligand 1 expressionManagement of BMSole metastatic siteStage IV diseaseWhole brain radiotherapyLigand 1 expressionPD-L1 expressionProspective clinical trialsTime of diagnosisManagement of patientsCell lung cancerCancer-related deathGenetic alterationsCentral nervous systemGenetic driver alterationsAnaplastic lymphoma kinaseEpidermal growth factor receptorGrowth factor receptorUpfront radiotherapy
2022
Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening
Joung R, Mullett T, Kurtzman S, Shafir S, Harris J, Yao K, Bilimoria K, Cance W, Nelson H, Abedi A, Acharya S, Adams K, Agarwal R, Agarwal S, Ahmad R, Albaneze P, Aldis K, Allen A, Allman S, Alsen M, Ansteth M, Appiah A, Arentz C, Arias A, Armetta C, Arnold A, Arsene C, Arthur K, Ashton B, Atassi M, Attia S, Bahna H, Bailen L, Baker T, Balan S, Balis A, Balsley A, Barajas D, Barone J, Batchelor B, Bates E, Bayliss T, Beck S, Bennett B, Bennett R, Bennett N, Bensenhaver J, Berby-Todd J, Berrocal J, Bertoni D, Bevan A, Bhatti R, Bier-Laning C, Blackwood M, Blake K, Blankner J, Blansfield J, Blaszkowsky L, Blonigen B, Bloom D, Boatsman J, Boggs J, Bold R, Bollinger D, Bolton C, Boolbol S, Boone G, Borges L, Bouton M, Bovest C, Bowman Seitz T, Boyer C, Boyle C, Bracho F, Bragg A, Branton S, Breslin T, Brock M, Broder A, Brown C, Brown B, Brown H, Brown L, Brown R, Bruce L, Bruce S, Bruton C, Bryant K, Burak W, Burgers J, Busch K, Caba D, Cain J, Campbell M, Campo C, Canavan L, Cannick L, Caputo P, Carr H, Casteel C, Cattaneo S, Cecil A, Celano P, Chambers K, Chambers S, Chin J, Christian M, Chu C, Church A, Clark J, Clark L, Clements M, Cohen S, Cole C, Colemire D, Compton J, Connery C, Constanza-Guaqueta D, Contreras S, Coon A, Copelen K, Corral J, Cosio R, Costas K, Cox A, Cox J, Crane E, Crotzer D, Cruz C, Cygan A, Cyphers L, Czerlanis C, Dale P, Danak S, Dang P, Darcourt J, Davuluri R, Day B, DeAntonio P, Der Y, DiAddezio N, Dietrich L, Diller E, Dodge T, Domenech G, Donovan D, Dubil E, Dunn G, Ebling L, Edsall B, Eftimie B, El Mouallem N, Eladoumikdachi F, Elliott J, Elliott K, Ellis M, Endo K, England T, Ennis C, Everhart T, Evins A, Facktor M, Fadel C, Farrell M, Fawley D, Feldman E, Finan M, Fintel A, Fleshman J, Fogarty S, Fontanilla H, Fontenot E, Foran J, Foss-Blizard C, Frank J, Franz J, Freeman L, Freter R, Fried S, Gabriel R, Galbraith J, Garcia J, Gardner K, Geary K, Gemmel D, Gerlach J, Ghee L, Ghisoli M, Giannone D, Gibbons C, Gillis P, Gilmore D, Gonzalez V, Gooley L, Gorrell C, Grady S, Grew D, Grisby S, Guerra C, Guerriero J, Gupta K, Gynn M, Hafertepen L, Hale C, Hallenbeck R, Hals L, Hammons E, Haramati L, Harper N, Harris J, Harrison M, Harrison M, Hassapis J, Haverlock B, Hawley A, Hayden T, Hayes C, Hayes D, Headen C, Hehnly E, Heikens S, Heinzman S, Herring M, Hill M, Hirner P, Hobbs K, Hordyk H, Horning N, Howard D, Huang K, Hughes C, Hughes J, Huibregtse C, Huitt N, Hunsucker L, Inverso T, Irwin T, Isbell M, Jabbour N, Jackson M, Jackson R, Jacob-Perez S, Jafri N, Jahania S, Jarrett A, Jenkinson S, Johnson R, Johnson A, Johnson D, Johnson P, Johnston C, Jones R, Jones S, Joseph J, Joseph N, Joyner R, Juarez-Perez M, Kaczmarski K, Kakani V, Kamran A, Kanaan S, Kang T, Kannarkatt J, Kanneganti S, Kantharaj B, Kaufman H, Keeler V, Keiser S, Kennedy M, Khan I, Khan R, Kibel L, Kiernan M, Kim B, Kinnaird A, Kipping-Johnson K, Kirkland P, Kirshnan S, Klaff L, Kloss R, Klotz J, Knight S, Koch J, Kocheril P, Kodali D, Kohli M, Koko I, Kong A, Kozyreva O, Kraft L, Krisher S, Kruse E, Kupstas A, Kurian M, Kwait R, Lan C, Lanciano R, Lannon W, Laster S, LaTrenta L, Law S, Le I, Lean N, Leatherbury K, Lee J, Leete T, Legenza M, Leung W, Li J, Likhacheva A, Lingerfelt B, Llaguna O, Longo L, Loop M, Lopez N, Loporchio N, Lowney J, Lozoraitis C, Lu K, Lue D, Lush R, Luyimbazi D, Lyons D, Macedo F, Machenzie M, Mack D, Mack J, MacVicar J, Mah K, Mahoney K, Makani N, Makower D, Malad S, Maldonado C, Malik F, Malone A, Mantha S, Marczak K, Margolis N, Mashanic K, Mathison J, Mauzy T, Maxwell L, McAllaster J, McCarthy C, McClune J, McColgan J, McCusker T, McDaniel D, McFayden L, McGivney R, McGovern K, McKeever H, McManus S, McNair K, McNeil H, McRae J, Medrano C, Mehta P, Merrigan T, Meyers E, Mickey S, Miller J, Miller L, Miller S, Mink T, Miranda J, Mitchell M, Monroe J, Moore J, Morin-Ducote G, Moritz T, Morris P, Mukherjee S, Mullally S, Mulligan M, Mullins D, Mullins M, Munoz I, Murdock J, Myers S, Nair S, Nandamuri K, Nicholls J, Nick D, Nish A, Nowell A, Nowell K, O'Connor L, O'Neill J, O'Riordan M, Ogunkunle R, Opsasnick M, Ortiz C, Osgood R, Oxenberg J, Page B, Palmer J, Parikh D, Park D, Partin J, Passwater C, Patel M, Patrick J, Patterson S, Pearson L, Peiffer S, Peralta E, Peterson M, Pettus B, Pezzulo J, Pfarr M, Phelps C, Phillips L, Pick M, Piephoff J, Pinkston J, Piper J, Pollak S, Ponec R, Popalzai M, Pories S, Prieto R, Proctor K, Provost K, Prow D, Puc M, Purdon M, Quaranta B, Quinlan-Davidson S, Rabines A, Rahman R, Ramasubbaiah R, Ramírez-Solá M, Randolph D, Raskin E, Rasmussen L, Rasmussen N, Rasmussen R, Reed C, Reese S, Regis S, Reilly J, Reitherman R, Reneau C, Renfroe C, Renn C, Reyna C, Rieger-Christ K, Ringer R, Rizack T, Rizwan U, Robinson W, Robles-Rodriguez E, Rogers E, Ronk M, Rossidis G, Rovito M, Roy A, Roybal L, Ruggiero G, Ruskin R, Ryan J, Sachdeva K, Saffie A, Sall N, Salters D, Sanchez J, Sandborn J, Sarap M, Sarap M, Sasaki J, Schallenkamp J, Schilder L, Schlesinger K, Scholl J, Scoppetuolo M, Scott J, Sexton W, Seydel A, Shackour M, Shah A, Shah M, Sharif S, Shaw C, Shehata A, Shelton C, Shields R, Shilad S, Shively E, Shriner M, Siebentritt J, Singhal S, Sinha S, Sinha S, Slotkin J, Smith K, Smith S, Smith-Marrone S, Sobel L, Sobolewski A, Sobolewski R, Solomon N, Songy T, Sonnier F, Sorenson L, Sorto J, Souza W, Spector D, Spigelman Z, Steitz B, Stephens C, Stewart S, Stipec G, Stith B, Street H, Subramanian J, Sumrall M, Sundermeyer M, Syed A, Szwerc M, Tanner L, Tatum T, Taveira R, Taylor M, Taylor J, Teal C, Tello-Skjerseth C, Terhaar K, Terhar M, Thind R, Thomas K, Thompson N, Thomson C, Tieu B, Toke M, Tomita M, Tomkovich K, Tong E, Tothy P, Tran M, Travis-Soper K, Trikha G, Trikha G, Vasnani R, Veeramachaneni N, Veerapaneni A, Ventura-Cullen D, Vester D, Vinsky J, Visioni A, Vlaminck L, Wadhera A, Wagner J, Waits B, Walenga S, Walker M, Wallace L, Wallace J, Ward M, Warmington K, Wasley R, Watson K, Watson W, Waxman J, Weathersby R, Weaver E, Weber M, Weiselberg C, Wesen C, Wexler A, Weyer D, White P, White C, Whitefield K, Wilkinson R, Willey J, Williams V, Wilson J, Witt V, Wold H, Woodford D, Woomer S, Wray J, Yeh K, Yoon-Flannery K, Zera R, Zlomke M, Zummo K, Zwicky K. Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening. JAMA Network Open 2022, 5: e2242354. PMID: 36383381, PMCID: PMC9669819, DOI: 10.1001/jamanetworkopen.2022.42354.Peer-Reviewed Original ResearchConceptsCancer screeningPreintervention periodScreening interventionsCancer programsNational Quality Improvement CollaborativeQI studiesQI projectCancer-related deathQuality Improvement CollaborativeAdditional screening testInterrupted time series analysisNationwide quality improvementsQI supportPrimary outcomeCancer careHospital characteristicsIntervention periodPrepandemic periodQI interventionsMAIN OUTCOMEPreintervention trendsDisease sitesScreening testIntervention effectsQI teamsAttacking the public health crisis of hepatocellular carcinoma at its roots
Lee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.Peer-Reviewed Original ResearchConceptsHepatitis B virusLiver diseasePublic health crisisHepatocellular carcinomaChronic hepatitis B virusAlcohol-related liver diseaseNonalcoholic fatty liver diseaseChronic liver diseaseFatty liver diseasePrincipal risk factorsCancer-related deathSignificant mortality ratePrevention of HCCHealth crisisViral hepatitisTreatment advancesB virusRisk factorsCurable stageCommon causeRisk populationsHCC detectionRisk individualsMortality rateSurveillance programIncarceration status and cancer mortality: A population-based study
Oladeru OT, Aminawung JA, Lin HJ, Gonsalves L, Puglisi L, Mun S, Gallagher C, Soulos P, Gross CP, Wang EA. Incarceration status and cancer mortality: A population-based study. PLOS ONE 2022, 17: e0274703. PMID: 36112653, PMCID: PMC9481043, DOI: 10.1371/journal.pone.0274703.Peer-Reviewed Original ResearchConceptsPopulation-based studyStage of diagnosisCancer mortalityInvasive cancerCancer diagnosisOverall survival rateCancer-related deathImmediate post-release periodCause mortalityTumor RegistryCancer characteristicsCancer survivalWorse outcomesCancer preventionHigh riskSurvival rateCancerMortalityIncarceration statusAdult residentsStudy periodTreatment effortsDiagnosisFive yearsPost-release periodHuman WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation
Cai WL, Chen JF, Chen H, Wingrove E, Kurley SJ, Chan LH, Zhang M, Arnal-Estape A, Zhao M, Balabaki A, Li W, Yu X, Krop ED, Dou Y, Liu Y, Jin J, Westbrook TF, Nguyen DX, Yan Q. Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. ELife 2022, 11: e78163. PMID: 36043466, PMCID: PMC9584608, DOI: 10.7554/elife.78163.Peer-Reviewed Original ResearchConceptsBreast cancer cellsMetastatic breast cancerBreast cancerRibosomal gene expressionCancer cellsKnockdown of WDR5Vivo genetic screenReversible epigenetic mechanismsGenetic screenTranslation regulationTriple-negative breast cancerEpigenetic regulatorsEpigenetic mechanismsBreast cancer growthCancer-related deathTranslation efficiencyWDR5Novel therapeutic strategiesTranslation rateGene expressionCell growthAdvanced diseaseEffective therapyMetastatic capabilityPotent suppressionExpression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma
Luo W, Nagaria T, Sun H, Ma J, Lombardo J, Bassett R, Cao A, Tan D. Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma. Pathology & Oncology Research 2022, 28: 1610293. PMID: 35221802, PMCID: PMC8863590, DOI: 10.3389/pore.2022.1610293.Peer-Reviewed Original ResearchConceptsGastric cancerPrognostic valueGastric adenocarcinomaMcl-1Pathologic TNM stageDifferent treatment modalitiesCancer-related deathPotential prognostic valueFurther subgroup analysisNegative prognostic markerTumor heterogeneityDifferent molecular alterationsSOX9 expressionSPOCK1 expressionPrognostic roleCommon malignancyPoor prognosisTNM stageTreatment modalitiesSubgroup analysisPrognostic markerUnivariate analysisDisease prognosisDivergent differentiationMolecular alterationsCECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Science Translational Medicine 2022, 14: eabf5473. PMID: 35108062, PMCID: PMC9003667, DOI: 10.1126/scitranslmed.abf5473.Peer-Reviewed Original ResearchConceptsBreast cancer metastasisReticuloendotheliosis viral oncogene homolog ACancer metastasisImmune suppressionM2 macrophagesWorse metastasis-free survivalMetastatic breast cancerMetastasis-free survivalV-rel avian reticuloendotheliosis viral oncogene homolog ACancer-related deathPrimary breast tumorsMultiple mouse modelsNF-κB signalingImmunocompetent settingNuclear factor-κB family membersMetastasis-promoting genesDistant metastasisMetastatic sitesPrimary tumorEffective therapyBreast cancerMetastasis treatmentMouse modelBreast tumorsMetastasisPopulation-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
Han R, Yang H, Li Y, Ling C, Lu L. Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical Oncology 2022, 39: 213. PMID: 36175803, PMCID: PMC9522682, DOI: 10.1007/s12032-022-01814-9.Peer-Reviewed Original ResearchConceptsProstate cancer cellsProstate cancerHDAC3 inhibitorCancer cellsCancer-related deathAnti-cancer effectsVivo mouse modelAnti-cancer efficacyAnti-cancer activityMouse modelNew agentsSecond causeHDAC inhibitorsCancerNormal cellsInhibitorsValeric acidCellsCASP3 activityCulture systemDiseaseChemosensitizers
2021
Toward personalized treatment approaches for non-small-cell lung cancer
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine 2021, 27: 1345-1356. PMID: 34385702, DOI: 10.1038/s41591-021-01450-2.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCombination therapyMaintenance combination therapyRobust predictive biomarkersCancer-related deathPersonalized treatment approachesRational combination therapiesAdvanced NSCLCEarly diseasePredictive biomarkersClinical studiesCurrent treatmentCommon causePatient stratificationTreatment approachesTherapyNSCLCBreakthrough therapiesCancerClinical research areasImmunotherapyVast majorityCurrent understandingFuture roleImpact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma
Saffo S, Peng C, Salem R, Taddei T, Nagar A. Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma. Digestive Diseases And Sciences 2021, 67: 1409-1416. PMID: 33811566, PMCID: PMC8487432, DOI: 10.1007/s10620-021-06967-7.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBiliary drainageDuctal adenocarcinomaSingle-center cohort studyHigh-volume tertiary centerPancreatic head ductal adenocarcinomaBackgroundPancreatic ductal adenocarcinomaUse of chemotherapyMultidisciplinary treatment modelCancer-related deathImplementation of guidelinesDelivery of careElectronic medical recordsResectable diseaseCohort studySurgical complicationsSurvival benefitTertiary centerPostprocedure complicationsPreoperative jaundiceAppropriate indicationsMedical recordsTherapeutic endoscopistsOutcome dataPractice trendsTreatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung
Ramalingam S, Dinan M, Crawford J. Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. Clinical Lung Cancer 2021, 22: e646-e653. PMID: 33582071, DOI: 10.1016/j.cllc.2020.12.013.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMetastatic non-small cell lung cancerCommunity-based centersAcademic centersMetastatic non-small cell carcinomaNon-small cell carcinomaStudy periodPrimary end pointNational Cancer DatabaseCell lung cancerSquamous cell carcinomaCancer-related deathMost cancer-related deathsTreatment-related improvementOverall survivalSurvival gapSurvival disparitiesImproved survivalCell carcinomaLung cancerCancer DatabaseRetrospective analysisNew therapiesPatientsEnd point
2020
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2710-2718. PMID: 32998946, PMCID: PMC7747688, DOI: 10.1158/1055-9965.epi-20-0490.Peer-Reviewed Original ResearchConceptsCancer recurrence rateRecurrence rateRelative survival dataColorectal cancerSurvival dataColorectal cancer-related deathsDisease-specific survival dataStage II rectal cancerStage III colorectal cancerCancer-specific death ratesStage II colon cancerPopulation-based cancer registriesColorectal cancer interventionDiagnostic time periodsMetastatic recurrence ratesRate 6 monthsNonmetastatic colorectal cancerColorectal cancer recurrenceMonths of diagnosisAnnual recurrence rateEnd Results ProgramCancer-related deathColorectal cancer diagnosisDecision analytic modelMetastatic diseaseHPV 16/18/45 Are Not The Most Frequent Genotypes In Women Of African-American Descent: Analysis In Cervical Pap Smears Of Women In An Inner-City Hospital
Dababneh M, Birdsong G, Mosunjac M, Krishnamurti U. HPV 16/18/45 Are Not The Most Frequent Genotypes In Women Of African-American Descent: Analysis In Cervical Pap Smears Of Women In An Inner-City Hospital. American Journal Of Clinical Pathology 2020, 154: s92-s92. DOI: 10.1093/ajcp/aqaa161.202.Peer-Reviewed Original ResearchHR-HPV positive rateHPV genotyping resultsInner-city hospitalHR-HPVHPV genotypesCervical cancerHPV 16HPV genotyping assaysSpecific HPV genotypesHigh-risk HPVCancer-related deathCervical Pap smearsHigh-risk genotypesAfrican AmericansGenotyping resultsAA descentHPV 16/18/45HPV 18/45African American descentPap smearCervical cytologyPositive rateGenotype 16Hispanic womenINTRODUCTION/Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.Peer-Reviewed Original ResearchConceptsPrimary liver cancerExpert consensus statementCancer-related deathCell of originBiliary malignant tumorsStudy of CholangiocarcinomaGastrointestinal malignanciesHistological confirmationAvailable therapiesBiliary treeNew diagnostic toolsSilent presentationPatient outcomesConsensus statementMalignant tumorsLiver cancerCholangiocarcinomaAggressive natureAlarming mortalityCurrent diagnosisMolecular alterationsNon-invasive approachTumorsDiagnostic toolTherapySurveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Torres M, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers 2020, 12: 1422. PMID: 32486355, PMCID: PMC7352281, DOI: 10.3390/cancers12061422.Peer-Reviewed Original ResearchLiver diseaseHepatocellular carcinomaRisk factorsHCC surveillanceNAFLD patientsNon-alcoholic fatty liver diseasePrevalence of HCCFrequent primary liver cancerNon-alcoholic fatty liverNon-cirrhotic NAFLDNon-cirrhotic subjectsCause of cirrhosisTreatment of HBVChronic liver diseaseFatty liver diseasePrimary liver cancerCancer-related deathMain risk factorsGood clinical judgmentEarly HCC detectionDeaths/yearNew screening toolNAFLD epidemicHCV infectionLiver ultrasonography
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply